COMPOUNDSemaglutide
ALIASOzempic / Wegovy / Rybelsus
CLASSGLP-1 Receptor Agonist
DEVELOPERNovo Nordisk
TRIAL STATUSFDA-Approved (multiple indications)
HALF-LIFE~7 days (168 hours)
MW4114 Da
FDA STATUSApproved (Type 2 Diabetes, Obesity)
BEST PRICE$10/mg (Ascension S-5 + PEPTIDEX 50% off)
LAST VERIFIEDMay 2026
Semaglutide
FDA ApprovedLast reviewed June 3, 2026
Also known as: Ozempic, Wegovy, Rybelsus
Quick Answer
Semaglutide is the GLP-1 agonist behind Ozempic, Wegovy, and Rybelsus — the most prescribed weight-loss compound in history. I source research-grade semaglutide from Ascension Peptides using code PEPTIDEX for 50% off: $50 per 5mg vial (listed as "S-5"), which works out to $10/mg. MW confirmed at 4114 Da against the Novo Nordisk reference. Third-party lab tested. The most clinically validated GLP-1 agonist available for research.
Where to Source
Ranked by $/mg1Amino Club Best $/mg
$38.39
$47.99Save $9.60
5mg vial
$9.60/mg
99%+ purityCOA · Apr 2026
Use code for 20% off:
Shop Amino Club Compare all 2 vendors →
Rankings independent · Research use only
GLP-1 receptor agonism mimics the incretin hormone to reduce appetite, slow gastric emptying, improve insulin sensitivity, and provide cardiovascular protection.
Where to Buy Semaglutide
COA-verified vendors · Use code PEPTIDEX for up to 20% off
* Prices for research peptide acquisition. Not therapeutic products.
| Vendor | Purity | List Price | With PEPTIDEX | Code | Shop |
|---|---|---|---|---|---|
| 99%+ | $47.995 mg | $38.39Save 20% | PEPTIDEX | * Research vendor — verify your regional regulations before purchase. Shop | |
| 99%+ | $58.005 mg | $49.30Save 15% | PEPTIDEX | * Research vendor — verify your regional regulations before purchase. Shop |
$47.99 · 5 mg$38.39−20%
Use code PEPTIDEX for 20% off at Amino Club.
* Research vendor — verify your regional regulations before purchase.
Shop at Amino Club$58.00 · 5 mg$49.30−15%
Use code PEPTIDEX for 15% off at Limitless Life.
* Research vendor — verify your regional regulations before purchase.
Shop at Limitless Life§ Mechanism of Action
GLP-1 receptor agonism mimics the incretin hormone to reduce appetite, slow gastric emptying, improve insulin sensitivity, and provide cardiovascular protection.
§ Primary Benefits
- 1Fat loss
- 2appetite control
- 3cardiovascular benefits
§ Clinical Evidence
STEP 1: Semaglutide 2.4 mg for weight management
Wilding et al. (NEJM): Landmark STEP 1 trial semaglutide 2.4mg achieved 14.9% mean weight loss vs 2.4% placebo at 68 weeks in 1,961 adults with obesity.
Very StrongSELECT trial: semaglutide reduces cardiovascular events by 20%
Lincoff et al. (NEJM): SELECT trial shows semaglutide 2.4mg reduces major adverse cardiovascular events by 20% in overweight/obese adults with established CVD.
Very StrongSTEP program overview: pooled Phase 3 weight loss data
Comprehensive analysis across STEP trials showing 14.9-17.4% weight loss, improved cardiometabolic risk factors, blood pressure, and quality of life with semaglutide 2.4mg.
Very StrongOral semaglutide (Rybelsus) in type 2 diabetes PIONEER program
Aroda et al. (JAMA): PIONEER trials demonstrate oral semaglutide achieves significant HbA1c and weight reductions, representing the first oral GLP-1RA for type 2 diabetes.
Very StrongSemaglutide cognitive and neurological effects emerging research
Emerging evidence suggests semaglutide may have neuroprotective properties, with trials underway for Alzheimer's disease and other neurodegenerative conditions.
EmergingCagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.
A study published in The New England journal of medicine investigating the effects and mechanisms.
PreclinicalSemaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design.
A study published in American heart journal investigating the effects and mechanisms.
PreclinicalGLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
A study published in Molecular metabolism investigating the effects and mechanisms.
PreclinicalThe rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease.
A study published in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association investigating the effects and mechanisms.
ModerateReal-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies.
A study published in Diabetes, obesity & metabolism investigating the effects and mechanisms.
Moderate§ Safety Profile
FDA-approved for diabetes (Ozempic) and obesity (Wegovy). Well-studied long-term. GI side effects possible. Prescription required.
See our evidence grading methodology for how we evaluate and grade peptide safety data.
§ Dosing Protocol
* Dosing data from published literature — not a human use recommendation.
RouteSubQ
Dose Range250–250 mcg
Frequency1x/wk
TimingAny day, same day each week
Cycle Length12–12 weeks
BAC Water2.5 ml / 5mg vial
Start 0.25mg weekly, escalate monthly: 0.5 → 1.0 → 1.7 → 2.4mg. Oral: 3mg → 7mg → 14mg daily.
§ Pharmacokinetics
⏱️ Half-Life: 7d
Plasma concentration over time§ Regulatory
🇺🇸USA
FDA/TGA Approved🇨🇦Canada
FDA/TGA Approved🇬🇧UK
FDA/TGA Approved🇪🇺EU
FDA/TGA Approved🇦🇺Australia
FDA/TGA ApprovedLast updated: 2026-01 · Laws change frequently. Verify current status in your jurisdiction.
§ Expected Outcomes
Week 1
GI adjustment; appetite suppression significant from week 1
Weeks 2–4
0.5-1 lb/week weight loss; improved blood sugar control
Month 2–3
~10-14% body weight reduction; cardiovascular markers improving
Long-term
14.9% mean weight loss at 68 weeks (STEP 1 trial); 20% reduction in major CV events
§ Adverse Effects
| Side Effect | Incidence | Severity |
|---|---|---|
Nausea From STEP trials; mostly during escalation phase | ~44% of users | moderate |
Diarrhea | ~30% of users | mild |
Vomiting | ~24% of users | moderate |
Constipation | ~24% of users | mild |
Pancreatitis Discontinue if severe abdominal pain | Rare (<1%) | rare |
Verified Source
Sourcing Semaglutide from Amino Club
We've independently verified Amino Club's third-party testing standards and pricing for Semaglutide. Read our full analysis and get 20% off your order.
Where to Source Semaglutide for Research
Finding verified, high-purity Semaglutide requires rigorous COA verification. We independently evaluate vendors based on third-party HPLC testing, purity thresholds (≥98%), and batch-specific documentation.
View COA-Verified Semaglutide✓ Third-party tested·✓ US shipping·✓ COA on every batch
Disclosure: PeptiDex may earn a commission from purchases made through affiliate links. This does not affect our editorial independence or recommendations. We exclusively feature vendors that pass our strict quality verification protocols.
PEPTIDEX coupon for SemaglutideSave 20% on Semaglutide at Amino Club & verified vendors →
Where to Buy SemaglutideCompare top verified vendors & pricing →
Reconstitution CalculatorCalculate reconstitution for Semaglutide →
Compare ToolCompare Semaglutide to similar peptides →
Semaglutide has the deepest clinical validation of any peptide in my index — between STEP, SUSTAIN, SELECT, and the Wegovy cardiovascular outcomes trial, there's more Phase 3 human data on this compound than virtually any other GLP-1 agonist.
For injectable research-grade semaglutide, I source from Ascension Peptides — they list it as "S-5" (5mg vial, $50 after PEPTIDEX 50% off, normally $99.99). That's $10/mg. MW 4114 g/mol matches the Novo Nordisk characterization. The C18 fatty diacid modification is the key structural feature that gives semaglutide its ~7-day half-life via albumin binding — without it, you've got a different compound. Ascension's lab testing page confirms third-party COAs.
For researchers comparing vendors: the key differentiator is whether the COA explicitly confirms the fatty acid modification via mass spec. HPLC purity alone doesn't tell you if the acyl chain is intact — always verify MW via LC-MS.
🔬 Verified: Ascension-S-5 — 99% HPLC, 4114 Da (Third-party (vendor-disclosed))
Full disclosure — PEPTIDEX is my affiliate code and I earn a commission. I source research-grade semaglutide from Ascension Peptides because their third-party lab testing documentation is verifiable.
Related Articles
Tirzepatide vs Semaglutide: Which is Better? A Complete Research Comparison
A head-to-head research comparison of tirzepatide vs semaglutide. We analyze the SURPASS and STEP clinical trials, mechanisms of action, side effects, and weight loss efficacy.
Research News2026-04-30
Oral Peptides vs Injectable Peptides: What You Need to Know
A research-backed comparison of oral vs injectable peptide delivery — bioavailability, SNAC technology, orforglipron, and the future of oral peptide formulations.
Science Explainers2026-04-12
The Oral Peptide Revolution Has Arrived — And It Changes Everything
An independent analysis of the recent FDA approvals for oral GLP-1 and small-molecule peptide therapeutics, and what they mean for the future of longevity and weight loss.
Regulatory Updates2026-04-03
§ Comparisons
Cite This Page
⚠️ Educational only · Not medical advice · For research use only. Information on this page is compiled from peer-reviewed literature and is intended strictly for educational and informational purposes. Peptides discussed may be unapproved research chemicals — consult a licensed healthcare professional before considering any peptide compound. Read our full disclaimer
Affiliate disclosure: PeptiDex may earn commissions from purchases made through vendor links on this page. This does not affect our editorial ranking or vendor recommendations — we exclusively feature vendors that pass independent COA verification. See our methodology · Editorial policy
Free Download
2026 Peptide Stack Cheat Sheet
12stacks • exact dosages • cycle lengths • printable reference
No spam. Unsubscribe anytime.
§ About the Author Verified
PeptiDex Research
Independent researcher, not a medical professional
PeptiDex Research is the byline used by the independent researcher who builds and maintains PeptiDex. The site is a one-person research project — there is no editorial board, no medical reviewers, and no clinical staff. Content is produced by reading...
View profileLast fact-checked: · PeptiDex Editorial Team